Notícias

INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.

JNJ's MONARCH QUEST 3 wins FDA 510(k) clearance, adding AI-powered planning, navigation and imaging upgrades for robotic bronchoscopy.

Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.

BTSG's nearly 59% YTD surge is backed by 23% revenue growth, rising margins and expansion in specialty pharmacy and home-based care.

SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.

Recent share performance and business backdrop West Pharmaceutical Services (WST) has drawn investor attention after a period where the stock returned 0.1% over the past month and 11.6% over the past 3 months, against a backdrop of steady reported operations. The company reports annual revenue of US$3.3b and net income of US$564.9m, supported by two primary segments. Proprietary Products contribute US$2.7b and West Vantage, which sits within that portfolio, adds US$600.6m. See our latest...

BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.

Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.

MMED's MiniMed Flex is now shipping in the U.S. with Abbott's 15-day Instinct sensor, pairing discreet app control with automated insulin delivery.

Smith+Nephew's five-year Imperial College London partnership targets less invasive robotic surgery and could speed research into clinical use.

Hinge Health's nearly 90% YTD surge is backed by 53% revenue growth, wider margins and expansion into migraine and GI care, but execution risks remain.

ISRG is expanding in Asia Pacific with a new Penang plant to boost capacity and support rising demand for robotic-assisted surgery.

Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.

SNN launches the FLOW FLEXTEND COBLATION Wand, offering adjustable-angle access and precise tissue removal in complex joint procedures.

CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.

NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.

West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.

West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.

WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.

WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.

West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.

BTSG's specialty, infusion and home health momentum support growth, while IRA pressure and customer exits may weigh on near-term margins.

NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.

West Pharmaceutical Services has delivered a strong 46.9% share price return over the past year, and the stock now sits in a zone where its intrinsic value estimate looks roughly in line with the market while several valuation checks flag a richer pricing backdrop. Over the last 12 months, West Pharmaceutical Services has returned 46.9%, which puts extra focus on whether that gain already reflects most of the company’s fundamental strengths. Following recent earnings updates that highlighted...

Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.

RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.

INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.

IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.

Management put a much higher number on its future, and the stock has been on a tear ever since. But is this a fleeting AI boom or a fundamental rewiring of the business.